Get started
Author

Paolo Cicogna

JAK2V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis
2022 · Paola Guglielmelli, Barbara Mora, et al. · Blood · 8
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
2023 · A. Atanasio, A. Vanni, et al. · Leukemia Research · 1
PDF
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis Score in Primary Myelofibrosis
2025 · Raffaella Santi, Giacomo Coltro, et al. · Modern Pathology
PDF
Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera
2024 · Paola Guglielmelli, Chiara Maccari, et al. · Blood
PDF
Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF)
2023 · Giacomo Coltro, Raffaella Santi, et al. · Blood
PDF
The Reticulin, Collagen, Osteosclerosis (RCO) Score Is Clinically and Prognostically Relevant in Patients with Secondary Myelofibrosis (SMF)
2023 · Giacomo Coltro, Raffaella Santi, et al. · Blood
PDF
Works count: 6
Citation count: 9
H-index: 1
I10-index:
Year
Topic
Type